CV Sciences outlines new non-cannabinoid product launches in 2026 while adapting to regulatory changes
Source: SeekingAlpha
2025-11-13 18:02:43 ET
More on CV Sciences
- CV Sciences, Inc. (CVSI) Q3 2025 Earnings Call Prepared Remarks Transcript
- CV Sciences, Inc. (CVSI) Q2 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on CV Sciences
- Financial information for CV Sciences
Read the full article on Seeking Alpha
For further details see:
CV Sciences outlines new non-cannabinoid product launches in 2026 while adapting to regulatory changes
CV Sciences Inc.
NASDAQ: CVSI
CVSI Trading
6.92% G/L:
$0.0649 Last:
295,507 Volume:
$0.0616 Open:
CVSI Latest News
February 26, 2026 08:30:00 am
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
December 22, 2025 07:00:00 pm
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
November 10, 2025 06:15:00 pm
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
CVSI Stock Data
$6,817,756
177,261,643
0.54%
5
N/A
Pharmaceuticals
Healthcare
US
San Diego
